Controlled clinical trial comparing flurbiprofen and phenylbutazone in patients with rheumatoid arthritis

Preliminary results in 12 patients with rheumatoid arthritis are presented from an on-going double-blind, between patient comparison of flurbiprofen and phenylbutazone. Patients received either 300 mg flurbiprofen daily or 400 mg phenylbutazone daily over a 2-week treatment period. Two patients treated with phenylbutazone developed a rash, and treatment was discontinued in 1 of them after Day 2.